DXS International (AQSE:DXSP) ROCE %: -7.67% (As of Apr. 2025)


What is DXS International ROCE %?

DXS International AQSE:DXSP ROCE % is -7.67% as of Apr. 2025. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. DXS International's annualized ROCE % for the quarter that ended in Apr. 2025 was -7.67%.

DXS International  (AQSE:DXSP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

DXS International ROCE % Related Terms

DXS International ROCE % Historical Data

* Premium members only.

The historical data trend for DXS International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International ROCE % Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 -1.05 -0.74 -121.77 -7.67

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 6.05 -1.05 -0.74 -121.77 -7.67

DXS International ROCE % Calculation

DXS International's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-0.127/( ( (2.661 - 0.811) + (2.371 - 0.909) )/ 2 )
=-0.127/( (1.85+1.462)/ 2 )
=-0.127/1.656
=-7.67 %

DXS International's ROCE % of for the quarter that ended in Apr. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2025 )  (Q: Apr. 2024 )(Q: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2025 )  (Q: Apr. 2024 )(Q: Apr. 2025 )
=-0.127/( ( (2.661 - 0.811) + (2.371 - 0.909) )/ 2 )
=-0.127/( ( 1.85 + 1.462 )/ 2 )
=-0.127/1.656
=-7.67 %

(1) Note: The EBIT data used here is one times the annual (Apr. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -7.67% mean?
DXS International (AQSE:DXSP) has a ROCE % of -7.67% as of Apr. 2025.
Is DXS International's ROCE % too high?
DXS International's current ROCE % is -7.67%.
How does DXS International's ROCE % compare to VEEV and BTSG?
DXS International's ROCE % of -7.67% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current ROCE % is -7.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current ROCE % is -7.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current ROCE % is -7.67% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.